Latest Close
₹26,145.00
+2.47%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹26,730.80
200 DMA
₹26,861.65
1 year gain / loss
−₹3,455.00(-11.67%)
₹29,600.00 → ₹26,145.00· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period unavailable · Consolidated figures where available
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company’s products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.
Market Cap
₹54,385.76 Cr
P/E
33.68×
Sector -38.72× · above
P/B
11.39×
Sector 4.11× · above
EV / EBITDA
23.19×
Sector 19.14× · above
ROE
37.86%
Sector 0.37%
ROCE
54.90%
Sector 6.55%
ROA
33.03%
Sector -17.04%
Cash Flow / Profit
-
Dividend
24 Jul 2026 · ₹525
Dividend
24 Jul 2026 · ₹131